The price of CymaBay Therapeutics Inc. (NASDAQ:CBAY) shares last traded on Wall Street fell -0.76% to $11.74.
Based on available information, 11 analysts follow CymaBay Therapeutics Inc. (NASDAQ:CBAY). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $19.00 and a low of $8.00, we find $15.50. Given the previous closing price of $11.83, this indicates a potential upside of 31.02 percent. CBAY stock price is now 21.20% away from the 50-day moving average and 58.93% away from the 200-day moving average. The market capitalization of the company currently stands at $1.11B.
Among analysts, 0 rate the stock a hold while 11 rate it a buy. Brokers who have rated the stock have averaged $14.80 as their price target over the next twelve months.
In other news, McWherter Charles, President of R&D sold 21,749 shares of the company’s stock on Jul 18. The stock was sold for $248,519 at an average price of $11.43. Upon completion of the transaction, the President of R&D now directly owns 15,000 shares in the company, valued at $0.18 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 14, General Counsel Quinlan Paul T sold 5,000 shares of the business’s stock. A total of $59,050 was realized by selling the stock at an average price of $11.81. Insiders disposed of 173,598 shares of company stock worth roughly $2.04 million over the past 1 year. A total of 0.31% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CBAY stock. A new stake in CymaBay Therapeutics Inc. shares was purchased by BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC during the first quarter worth $29,350,000. CORMORANT ASSET MANAGEMENT, LP invested $14,927,000 in shares of CBAY during the first quarter. In the first quarter, VOLORIDGE INVESTMENT MANAGEMENT, LLC acquired a new stake in CymaBay Therapeutics Inc. valued at approximately $7,558,000. JENNISON ASSOCIATES LLC acquired a new stake in CBAY for approximately $7,322,000. HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND purchased a new stake in CBAY valued at around $4,539,000 in the second quarter. In total, there are 162 active investors with 76.30% ownership of the company’s stock.
A candlestick chart of CymaBay Therapeutics Inc. (NASDAQ: CBAY) showed a price of $11.64 on Tuesday morning. During the past 12 months, CymaBay Therapeutics Inc. has had a low of $3.02 and a high of $12.43. As of last week, the company has a debt-to-equity ratio of 0.91, a current ratio of 5.20, and a quick ratio of 5.20. The fifty day moving average price for CBAY is $9.69 and a two-hundred day moving average price translates $7.39 for the stock.
The latest earnings results from CymaBay Therapeutics Inc. (NASDAQ: CBAY) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.29, missing analysts’ expectations of -$0.09 by -0.2. This compares to -$0.32 EPS in the same period last year. The company reported revenue of $26.88 million for the quarter, compared to $24.5 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 9.68 percent. For the current quarter, analysts expect CBAY to generate $12.8M in revenue.
CymaBay Therapeutics Inc.(CBAY) Company Profile
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
